Frontiers in pharmacology. 2025 May 30:16:1566604. doi: 10.3389/fphar.2025.1566604 Q14.82025
Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis
贝伐单抗联合新辅助化疗治疗卵巢癌的疗效和安全性系统评价和meta分析 翻译改进
Yijun Wang 1, Yicong Wang 1, Lei Wang 1, He Yuan 1, Yongai Yu 1, Daju Liu 1
作者单位 +展开
作者单位
DOI: 10.3389/fphar.2025.1566604 PMID: 40520171
摘要 中英对照阅读
目标: 评估贝伐单抗在卵巢癌新辅助化疗中的有效性和安全性，通过系统评价和meta分析进行评估。
方法: 使用“Ovarian Neoplasms”、“Bevacizumab”、“Monoclonal antibodies against vascular endothelial growth factor”、“Avastin” 和 “Neoadjuvant Therapy”等关键词在PubMed、Embase和Cochrane Library等在线数据库中搜索有关接受新辅助化疗加用贝伐单抗方案后进行间期减瘤手术的卵巢癌患者的治疗相关文章。然后使用Stata 15.0软件对筛选出的文献，包括随机对照试验和队列研究进行了meta分析。
结果: 该meta分析共纳入了五篇符合条件的研究论文。实验组有160名患者接受了紫杉醇+卡铂+贝伐单抗的新辅助化疗（TCB），而对照组则有211名患者仅接受紫杉醇+卡铂治疗 (TC) 。结果显示，两组在满意肿瘤减灭率方面没有显著差异（RR = 1.124, 95% CI: 0.947-1.335, P = 0.182；异质性：I²= 40.3%， p = 0.152）和无进展生存期（PFS）(HR = 0.74，95% CI: 0.48-1.14, p = 0.173；异质性：I²= 86%，p = 0.007)。新辅助化疗中使用贝伐单抗并不会增加化疗的不良事件发生率（RR = 0.88，95% CI: 0.713-1.088, p = 0.238；异质性：I²= 49.5%，p = 0.095）。TCB组术后并发症的发生率与TC组相比没有显著差异（RR = 0.955，95% CI: 0.672-1.359, p = 0.799；异质性：I²= 6.8%，p = 0.368）。
结论: 在卵巢癌新辅助化疗中使用贝伐单抗是安全可行的，但并未显著改善间期减瘤术的满意肿瘤减少率，并且对延长术后无进展生存期没有影响。因此，在预防性化疗中使用贝伐单抗应该谨慎考虑。
系统综述注册: https://inplasy.com/inplasy-2024-12-0065/, INPLASY2024120065.
关键词: Avastin；贝伐单抗；抗血管内皮生长因子单克隆抗体；新辅助化疗；卵巢肿瘤。
相关内容
-
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer
新辅助化疗联合或不联合贝伐单抗治疗晚期卵巢癌的GEICO 1205随机II期临床试验的有效性和安全性结果
Yolanda Garcia Garcia et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2019 Jul;29(6):1050-1056.
-
Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients
贝伐单抗新辅助化疗治疗晚期盆腔/卵巢癌患者的安全性和有效性研究
Soshi Kusunoki et al.
Taiwanese journal of obstetrics & gynecology. 2018 Oct;57(5):650-653.
-
Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer
新辅助化疗方案中包含贝伐单抗后的晚期卵巢癌手术并发症及病理缓解情况
Elisabeth Chéreau
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2013 Sep;23(7):1326-30.
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)
新辅助化疗联合或不联合贝伐单抗治疗晚期卵巢癌的肿瘤微环境变化分析（GEICO-89T/MINOVA研究）
Beatriz Tavira et al.
Clinical cancer research : an official journal of the American Association for Cancer Research. 2024 Jan 5;30(1):176-186.
-
Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
日本医疗索赔数据库中，贝伐单抗联合新辅助化疗一线治疗晚期卵巢癌、输卵管癌或腹膜癌的胃肠道穿孔发生率分析
Akihiko Ueda et al.
Journal of gynecologic oncology. 2022 Nov;33(6):e78.
-
Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer
新诊断为初次不可切除的卵巢癌患者在接受新辅助化疗后进行完全细胞减灭术联合顺铂腹腔热灌注治疗后维持贝伐单抗治疗的一项多中心I期剂量递增研究结果
S Gouy et al.
Gynecologic oncology. 2016 Aug;142(2):237-42.
-
Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
腹腔注射贝伐单抗顺铂联合紫杉醇与静脉注射顺铂联合紫杉醇新辅助化疗治疗晚期卵巢癌的疗效比较
Yin Tao et al.
Frontiers in medicine. 2022 Mar 9:9:807377.
-
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
新辅助化疗联合或不联合贝伐单抗妇女的泛生殖系基因组-wide关联研究
James N Ingle et al.
Pharmacogenetics and genomics. 2018 Jun;28(6):147-152.
